Fenwick & West LLP represented Oncothyreon Inc. (NASDAQ: ONTY) in its concurrent but separate underwritten offerings of 10,000,000 shares of its Common Stock at a price to the public of $2.00 per share and 10,000 shares of its Series A Convertible Preferred Stock at a price to the public of $2,000.00 per share. As part of the Common Stock offering, Oncothyreon also granted the underwriters a 30-day option to purchase 1,500,000 additional shares of Common Stock. The expected gross proceeds for both offerings combined is $43 million, which reflects the exercise in full of the underwriters option to purchase additional shares of Common Stock.
Cowen and Company, LLC acted as the sole book-running manager, and H.C. Wainwright & Co., LLC acted as the co-manager.
The Fenwick transaction team included corporate attorneys Effie Toshav, James Evans, Niki Fang, Amanda Rose, Ryan McRobert and Hans Andersson.